Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect

Stock Information for Aytu BioPharma, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aytu BioPharma, Inc.

Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025
Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies
Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress
Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia
Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025
Bionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting
Bionano to Participate in the H.C. Wainwright @ Home Event
Bionano Genomics, Inc. Announces Closing of $10 Million Public O?ering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.